KZIA - Kazia Therapeutics Reaches Primary Endpoint and Concludes Clinical Trial Early

2024-02-21 08:38:39 ET

DENVER, Colo., 21 Feb, 2024 (www.247marketnews.com)- Kazia Therapeutics Limited (NASDAQ: KZIA ) reported an early conclusion, based on positive safety and promising clinical response findings observed to date of an important two-part Phase I trial, on its investigator-initiated trial, which evaluated the use of paxalisib (an oral PI3K/mTOR dual inhibitor) with radiation therapy for the treatment of patients with PI3K pathway mutation brain metastases from solid tumors.

KZIA is trading at $0.43, up $0.03 (+7.86%), on 10.91M premarket shares traded.

KZIA’s 52-week range is $0.24 to $1.68. It hit its 52-week low earlier this month and its next key inflection points are yesterday’s $0.435 high and 48-cents.

Kazia’s CEO, Dr. John Friend, said, “We are extremely excited about these findings, which include not only encouraging safety data but also some promising efficacy signals for paxalisib in combination with radiation therapy. We are now preparing to engage with the Food and Drug Administration to discuss the data and seek guidance on the conduct of a pivotal registration study, with the goal of rapidly progressing paxalisib’s development to potentially provide a more effective treatment option for patients with brain metastases.”

The post Kazia Therapeutics Reaches Primary Endpoint and Concludes Clinical Trial Early first appeared on 24/7 MarketNews .

For further details see: